Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Enlight Biosciences Creates Entrega
by Ann M. Thayer
January 17, 2011
| A version of this story appeared in
Volume 89, Issue 3
Enlight Biosciences, a Boston-based firm established by PureTech Ventures and backed by several major pharmaceutical companies, has created an independent company called Entrega. The new firm will develop oral drug delivery technologies for administering proteins, peptides, and difficult-to-deliver small molecules. For its initial development work, Entrega will create orally bioavailable formulations of several biologic drugs from Enlight’s company partners. In return, Entrega will receive undisclosed up-front and research milestone payments.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter